◆英語タイトル:ViaCyte Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013254
◆発行会社(調査会社):
GlobalData
◆発行日:2017年11月28日
◆ページ数:36
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
ViaCyte Inc (ViaCyte), formerly Novocell, Inc. is a regenerative medicine company that focuses on the development of cell replacement therapies for the treatment of diabetes. The company’s pipeline product portfolio includes VC-01, which is being developed as a therapy for T1D patients who have minimal to no insulin-producing beta cell function; and PEC-Direct, for type 1 diabetes patients that have glycemic lability, hypoglycemic episodes, and impaired hypoglycemia awareness. Its PEC-Direct product candidate delivers the pancreatic progenitor cells in a non-immunoprotective device. The company works in partnership with academic, commercial and not-for-profit institutions. ViaCyte is headquartered in San Diego, California, the US.
ViaCyte Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
ViaCyte Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
ViaCyte Inc, Medical Devices Deals, 2011 to YTD 2017 9
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
ViaCyte Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
ViaCyte Raises USD10 Million in Financing 11
ViaCyte Raises Additional USD5.4 Million in Series C-1 Venture Financing 12
ViaCyte Raises USD15 Million in Venture Financing 13
Partnerships 14
ViaCyte Enters into Research Agreement with W. L. Gore & Associates 14
Licensing Agreements 15
ViaCyte Enters into Licensing Agreement with Janssen Biotech 15
Takara Bio Enters into Licensing Agreement with ViaCyte 16
ViaCyte Enters into Option for Licensing Agreement with Janssen Research & Development 17
Nestle Institute of Health Sciences Enters into Licensing Agreement with ViaCyte 18
Cellular Dynamics Enters Into Licensing Agreement With ViaCyte 19
ViaCyte Inc – Key Competitors 20
ViaCyte Inc – Key Employees 21
ViaCyte Inc – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Product News 23
11/04/2016: ViaCyte Announces Presentation on VC-01 at Healthcare Events in November 23
11/04/2016: ViaCyte to Present on PEC-Direct at Healthcare Events in November 24
10/04/2016: ViaCyte to Provide an Update on PEC-Direct at 2016 Cell and Gene Meeting on the Mesa 25
10/04/2016: ViaCyte to Provide an Update on VC-01 at 2016 Cell and Gene Meeting on the Mesa 26
07/21/2016: ViaCyte Awarded New CIRM Grant to Develop PEC-Direct for High-Risk Type 1 Diabetes 27
05/22/2017: JDRF and ViaCyte Announce Support for Development of PEC-Direct Cell Replacement Therapy for Type 1 Diabetes 28
04/20/2016: ViaCyte to Present at Healthcare Events in April and May 29
03/01/2016: ViaCyte to Present at JDRF TypeOneNation Summit Meetings in Washington DC and Los Angeles 30
02/23/2017: Beyond Type 1 Provides Grant to ViaCyte to Support Research and Development of Cell Replacement Therapy PEC-Direct for Type 1 Diabetes 31
02/23/2017: Beyond Type 1 Provides Grant to ViaCyte to Support Research and Development of Cell Replacement Therapy PEC-Encap for insulin-requiring diabetes 32
01/06/2016: ViaCyte to Present at Biotech Showcase 2016 in San Francisco 33
Product Approvals 34
May 22, 2017: ViaCyte Receives IND Allowance from FDA and Clearance from Health Canada to Commence International Clinical Trial of PEC-Direct Cell Therapy for High-Risk Type 1 Diabetes 34
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36
List of Tables
ViaCyte Inc, Pharmaceuticals & Healthcare, Key Facts 2
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
ViaCyte Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
ViaCyte Inc, Deals By Therapy Area, 2011 to YTD 2017 8
ViaCyte Inc, Medical Devices Deals, 2011 to YTD 2017 9
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
ViaCyte Raises USD10 Million in Financing 11
ViaCyte Raises Additional USD5.4 Million in Series C-1 Venture Financing 12
ViaCyte Raises USD15 Million in Venture Financing 13
ViaCyte Enters into Research Agreement with W. L. Gore & Associates 14
ViaCyte Enters into Licensing Agreement with Janssen Biotech 15
Takara Bio Enters into Licensing Agreement with ViaCyte 16
ViaCyte Enters into Option for Licensing Agreement with Janssen Research & Development 17
Nestle Institute of Health Sciences Enters into Licensing Agreement with ViaCyte 18
Cellular Dynamics Enters Into Licensing Agreement With ViaCyte 19
ViaCyte Inc, Key Competitors 20
ViaCyte Inc, Key Employees 21
ViaCyte Inc, Subsidiaries 22